Cargando…

Ceftriaxone-induced hemolysis

Immune hemolytic anemia is a rare adverse effect of ceftriaxone, a third-generation cephalosporin, which is a commonly used antibiotic. We describe a 60-years-old lady, a case of community-acquired pneumonia, who developed severe hemolysis after the first dose of ceftriaxone. Her hemoglobin dropped...

Descripción completa

Detalles Bibliográficos
Autores principales: Guleria, Vivek S., Sharma, Nitin, Amitabh, Sagar, Nair, Velu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3793531/
https://www.ncbi.nlm.nih.gov/pubmed/24130395
http://dx.doi.org/10.4103/0253-7613.117758
_version_ 1782477833603383296
author Guleria, Vivek S.
Sharma, Nitin
Amitabh, Sagar
Nair, Velu
author_facet Guleria, Vivek S.
Sharma, Nitin
Amitabh, Sagar
Nair, Velu
author_sort Guleria, Vivek S.
collection PubMed
description Immune hemolytic anemia is a rare adverse effect of ceftriaxone, a third-generation cephalosporin, which is a commonly used antibiotic. We describe a 60-years-old lady, a case of community-acquired pneumonia, who developed severe hemolysis after the first dose of ceftriaxone. Her hemoglobin dropped from 9.6 g /dl to 5.5 g /dl. However, she improved after discontinuation of the drug and blood transfusion. This report serves as a reminder to medical fraternity that life-threatening hemolysis can rarely follow administration of ceftriaxone.
format Online
Article
Text
id pubmed-3793531
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-37935312013-10-15 Ceftriaxone-induced hemolysis Guleria, Vivek S. Sharma, Nitin Amitabh, Sagar Nair, Velu Indian J Pharmacol Drug Watch Immune hemolytic anemia is a rare adverse effect of ceftriaxone, a third-generation cephalosporin, which is a commonly used antibiotic. We describe a 60-years-old lady, a case of community-acquired pneumonia, who developed severe hemolysis after the first dose of ceftriaxone. Her hemoglobin dropped from 9.6 g /dl to 5.5 g /dl. However, she improved after discontinuation of the drug and blood transfusion. This report serves as a reminder to medical fraternity that life-threatening hemolysis can rarely follow administration of ceftriaxone. Medknow Publications & Media Pvt Ltd 2013 /pmc/articles/PMC3793531/ /pubmed/24130395 http://dx.doi.org/10.4103/0253-7613.117758 Text en Copyright: © Indian Journal of Pharmacology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Drug Watch
Guleria, Vivek S.
Sharma, Nitin
Amitabh, Sagar
Nair, Velu
Ceftriaxone-induced hemolysis
title Ceftriaxone-induced hemolysis
title_full Ceftriaxone-induced hemolysis
title_fullStr Ceftriaxone-induced hemolysis
title_full_unstemmed Ceftriaxone-induced hemolysis
title_short Ceftriaxone-induced hemolysis
title_sort ceftriaxone-induced hemolysis
topic Drug Watch
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3793531/
https://www.ncbi.nlm.nih.gov/pubmed/24130395
http://dx.doi.org/10.4103/0253-7613.117758
work_keys_str_mv AT guleriaviveks ceftriaxoneinducedhemolysis
AT sharmanitin ceftriaxoneinducedhemolysis
AT amitabhsagar ceftriaxoneinducedhemolysis
AT nairvelu ceftriaxoneinducedhemolysis